Korea Accelerating Efforts To Develop, Launch Orphan Drugs
This article was originally published in PharmAsia News
South Korea is moving to speed up the development and launch of orphan drugs amid a growing need to ease medicine supply disruptions. Through revisions in rules, the government will make it easier to designate orphan drugs, which will undergo review 10 years after approval, rather than five years.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.